

To all stakeholders,

(Amendments) Amendments to “Non-consolidated Summary of
Financial Results for the Fiscal Year Ended March 31, 2022”

Perseus Proteomics Inc. (“the Company”) hereby announces amendments to “Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2022” announced on May 13, 2022. The amended parts are underlined.

1. Reasons for amendments

The Company has found some errors in “Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2022” after submission and now makes amendments.

2. Amendment details

- (1) Page 3 (1) Overview of business results of the fiscal year ended March 31, 2022
(Before amendment)

d. PPMX-T001

PPMX-T001 targets GPC3 which is highly expressed on liver cancer. Chugai Pharmaceutical Co., Ltd. (Chugai) was provided the rights to register the patents in 2006 and has been developing it in 2 different forms of a drug for liver cancer: GC33 and ERY974, however, the patent which is a subject of the agreement will expire on June 20, 2022. Accordingly, the agreement will terminate on the same date. There is no impact on the future income/profit of the Company from PPMX-T001 and the Company does not estimate any impact in its plan.

(After amendment)

d. PPMX-T001

PPMX-T001 targets GPC3 which is highly expressed on liver cancer. Chugai Pharmaceutical Co., Ltd. (Chugai) was provided the rights to register the patents in 2006 and has been developing it in 2 different forms of a drug for liver cancer: GC33 and ERY974, however, the patent which is a subject of the agreement will expire on June 21, 2022. Accordingly, the agreement will terminate on the same date. There is no impact on the future income/profit of the Company from PPMX-T001 and the Company does not estimate any impact in its plan.

(2) Page 5 2. Non-consolidated financial statements (1) Statement of balance sheet
(Before amendment)

(thousand yen)

	As of March 31, 2021	As of March 31, 2022
Non-current assets		
Property, plant and equipment		
Buildings	8,034	<u>13,860</u>
Accumulated depreciation	(8,034)	<u>(13,860)</u>
Buildings, net	0	0
Tools, furniture and fixtures	114,952	<u>278,388</u>
Accumulated depreciation	(114,952)	<u>(278,387)</u>
Tools, furniture and fixtures, net	0	0
Total property, plant and equipment	0	0

(After amendment)

(thousand yen)

	As of March 31, 2021	As of March 31, 2022
Non-current assets		
Property, plant and equipment		
Buildings	8,034	<u>8,043</u>
Accumulated depreciation	(8,034)	<u>(8,043)</u>
Buildings, net	0	0
Tools, furniture and fixtures	114,952	<u>115,594</u>
Accumulated depreciation	(114,952)	<u>(115,594)</u>
Tools, furniture and fixtures, net	0	0
Total property, plant and equipment	0	0

(3) Page 7 (2) Statement of income
(Before amendment)

(thousand yen)

	Fiscal year ended March 31, 2021	Fiscal year ended March 31, 2022
Non-operating expenses		
Commission expenses	4,433	—
Taxes and dues	3,527	9,346
Listing expenses	3,436	9,531
Other	<u>0</u>	0
Total non-operating expenses	11,397	18,878

(After amendment)

(thousand yen)

	Fiscal year ended March 31, 2021	Fiscal year ended March 31, 2022
Non-operating expenses		
Commission expenses	4,433	—
Taxes and dues	3,527	9,346
Listing expenses	3,436	9,531
Other	=	0
Total non-operating expenses	11,397	18,878

END